OncoSec Medical Inc (ONCSQ)

[ahab333]

AT this point with ONCS SP, I don't think this upgrade will so any good by Maxim & Noble Financial will do any good. Just way to much pressure that continues to stop this decent in shares unfortunately.

Whether one should buy more here? Who knows but I did at .98 yesterday and now not sure it's a good idea like catching a falling knife but I didn't get cut so far, GULP!

SEE below on the upgrades or continuance of confidence by these 2 plus Vanguard's stake in shares:

Link: http://bangaloreweekly.com/maxim-group-reiterates-buy-rating-for-oncosec-medical-inc-oncs-235526.html


BangaloreWeekly

Home
Business

The Maxim Group Reiterates Buy Rating for OncoSec Medical Inc (ONCS)

May 16, 2017 Donald glover
The Maxim Group Reiterates Buy Rating for OncoSec Medical Inc (ONCS)

OncoSec Medical Inc (NASDAQ:ONCS)‘s stock had its “buy” rating reissued by equities researchers at Maxim Group in a report issued on Friday.

The analysts wrote, “Oncosec announced a collaboration and supply agreement with Merck (MRK – $64.43 – NR) to evaluate Immunopulse IL-12 + Keytruda in the upcoming P2b study (PISCES) in metastatic melanoma that have progressed on PD-1 therapy.””

Separately, Noble Financial reaffirmed a “buy” rating on shares of OncoSec Medical in a research note on Friday.

OncoSec Medical (NASDAQ:ONCS) traded up 1.82% during midday trading on Friday, hitting $1.12. The stock had a trading volume of 91,319 shares. The firm has a 50 day moving average price of $1.20 and a 200 day moving average price of $1.36. OncoSec Medical has a one year low of $1.03 and a one year high of $2.08. The stock’s market cap is $23.37 million.

A hedge fund recently raised its stake in OncoSec Medical stock. Vanguard Group Inc. increased its position in OncoSec Medical Inc (NASDAQ:ONCS) by 34.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 564,106 shares of the biotechnology company’s stock after buying an additional 144,325 shares during the period. Vanguard Group Inc. owned approximately 2.70% of OncoSec Medical worth $722,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.39% of the company’s stock.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.